JP3517274B2 - Skin composition - Google Patents

Description

Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a plant-derived human interferon-inducing substance and a skin composition containing the same, which can be used for medical purposes and for the general public. [0002] Interferon (hereinafter abbreviated as IFN) was originally identified as a cytokine having an antiviral effect, but has now been found to have an extremely large number of biological activities. Among them, the most anticipated clinically is antitumor activity, and Hairy ce
High effects have been observed for ll leukemia, chronic myelogenous leukemia, malignant melanoma, etc. Various other clinical applications of IFN have been attempted, and IFN has been used for atopic dermatitis.
Is also an example. However, humans must be prescribed human IFN because of the species specificity of IFN. Therefore, recombinant human IFN is used clinically, but there are side effects caused by using recombinant,
There were problems such as that the effect was not as high as that of natural IFN produced from human-derived cells. As a means for solving these problems, an IF
It is conceivable that the body may produce IFN by administering an inducer of IFN instead of N itself.
This requires high safety of the IFN inducer to be administered. [0005] Poly I: C, LPS and the like are known as inducers of natural human IFN other than animal viruses, but they cannot be said to be harmless to the human body. In addition, a report on plant-derived IFN-inducing substances (Japanese Unexamined Patent Publication No.
19525, etc.), but since cells derived from mice and rabbits are used as IFN-producing cells, it is unclear whether they can produce species-specific IFN even in humans. . In addition, since these reports use a bioassay to measure IFN titers, they may be affected by cytokines that exhibit antiviral activity such as TNF that may be contained in the sample, The effects of these IFN inducers remain questionable. [0006] Therefore, there has been a demand for a highly safe IFN-inducing substance for human-derived cells. In addition, if IFN is produced in the skin by administering this inducer of IFN in the form of a skin composition, etc., it will not only exert an effect on tumors such as herpes and malignant melanoma caused by the virus, but also atopy. Improves skin roughness due to inflammation such as atopic dermatitis, increases the biological activity of IFN such as dermal matrix components by promoting hyaluronic acid production, and promotes collagenase production (see MRDuncan et al.
Arch. Dermatol. Res., 281, 11, 1989) is expected to produce fresh, elastic and healthy skin by promoting the metabolism of old collagen in the dermis. Accordingly, an object of the present invention is to provide a human interferon-inducing substance according to claim 1, wherein the human interferon-inducing substance is oren, bone crushing supplement, gold fruit lantern,
Kobana spiny beans, Mongo Koryosa, fine spices, white thorns, bitter beans, katsuki, thorns, chen skin, current evidence, ginger, peaches, yellow beans, spices, self defense,
A skin composition characterized by providing a highly safe natural human IFN-inducing substance by using turmeric, magnolia, safflower, shiitake, celery and banana, and containing the substance as an effective administration method thereof To provide things. Means for Solving the Problems In order to provide a natural human IFN inducer with high safety, IFN against human peripheral blood mononuclear cells in various well-known natural product samples has been conventionally known.
Eagerly conducting inducing ability tests, Oren, Bone Crushing, Kinkalan, Kobana Thorn Beans, Mongo Kureiso, Spicy, White Thorn, Mameko, Katsuki, Intercession,
The present inventors have found that extracts of Chen skin, present evidence, ginger, peach seeds, yellow pepper, spicy, self-defense, turmeric, magnolia, safflower, shiitake mushroom, celery, and banana have human IFN-inducing activity, and led to the present invention. Was. The method of extracting the human IFN-inducing substance is not particularly limited, and the extraction solvent may be a known buffer salt solution such as water or phosphate buffer, or a solvent such as methanol, ethanol, propanol, butanol and acetone. An appropriate concentration of an organic solvent and a solvent obtained by mixing two or more of them can be used. In this case, the extraction efficiency can be increased by performing the heat extraction. In addition, the buffer salt solution and the organic solvent are not limited to the types described above. The human IFN-inducing substance of the present invention has an IFN-inducing activity on human-derived cells. This effect is
This is supported by the following experiments and tests. Experimental Example 1 1 kg of dried bone crusher was crushed,
To this, 10 L of water was added, and extraction was performed at 60 ° C. for 24 hours. Separate the extract and residue by filtration, add 10 L of water to the residue,
After performing extraction at 0 ° C. for 24 hours, the extract obtained by filtration was combined with the above extract. The extract thus obtained was concentrated under reduced pressure, and then freeze-dried to obtain about 200 g of a bone rehydration extract. Test Example 1 The above bone extract rehydration extract was used as a test sample, and IFN against human peripheral blood mononuclear cells was determined by the following test method.
An inducibility test was performed. [0013] Heparin-supplemented peripheral blood is collected from a healthy person, and Fi
Peripheral blood mononuclear cells were obtained by a conventional method using coll-paque.
This was added to 1 × 10 ⁶ using RPMI1640 medium containing 10% FBS.
It was adjusted to cells / ml. 1 ml of this cell suspension
The human IFN obtained according to the method described in Experimental Example 1
A predetermined amount of an inducer was added, and the cells were cultured at 37 ° C. for 48 hours. The culture was centrifuged to recover the supernatant, and its IFN activity was measured. Sendai virus (hereinafter abbreviated as HVJ) was used as a positive control for IFN-α induction, and phytohemagglutinin (hereinafter abbreviated as PHA) was used as a positive control for IFN-γ induction. For the measurement of IFN activity, a fluorescent immunoassay using an anti-human leukocyte-derived natural IFN-α horse polyclonal antibody or an anti-human leukocyte-derived natural IFN-γ rabbit polyclonal antibody was used. By using an immunoassay rather than a bioassay, IFN is not affected by cytokines that exhibit antiviral activity, such as TNF.
Only N can be measured. Table 1 shows the test results when the test sample obtained in Experimental Example 1 was added so as to have the concentration shown in Table 1. IFN activities in the table are shown in international units. From the results shown in Table 1, human IFN-inducing activity was observed in the bone crushing rehydration extract. [Table 1] Test Example 2 Oren, Kinkalan, Kobana Thorn Beans, Mongo Koryosa, Spicy, White Thorn, Mameko, Katsuki, Ishige, Chenhide, Current Evidence, Ginger, Tomon, Yellow Gon , Xinyi, Self-defense, Turmeric, Thick,
Dried safflower and shiitake mushrooms were treated according to the method described in Experimental Example 1, and these were used as test samples to conduct an IFN-inducing ability test on human peripheral blood mononuclear cells according to the method described in Test Example 1. Table 2 shows the test results when each test sample obtained by treating according to the method described in Experimental Example 1 in Test Example 2 was added so as to have the concentration shown in Table 2. is there.
From the results in Table 2, it can be seen that Oren, Kinkalan, Kobana Thorn Beans, Mongo Koryosa, Spicy, White Thorn, Mameko, Katsuki, Qingwei, Chenpi, Current Evidence,
Extracts of ginger, peach tongue, yellow sesame, spicy, self-defense, turmeric, magnolia, safflower and shiitake mushrooms showed human IFN-inducing activity. [Table 2] Experimental Example 2 1 kg of mature raw banana fruit was placed in a mixer and pressed to obtain banana juice. At this time, water may be appropriately added to facilitate the pressing. The banana juice was freeze-dried to obtain about 50 g of a banana extract. Test Example 3 A celery extract obtained by treating the above banana extract and raw celery according to the method described in Experimental Example 2 was used as a test sample, and humans were processed according to the method described in Test Example 1. An IFN inducibility test was performed on peripheral blood mononuclear cells. Table 3 shows the test results when the banana extract or the celery extract was added to the concentration shown in Table 3. From the results shown in Table 3, the banana and celery extracts were found to have human IFN-inducing activity. [Table 3] Next, a formulation example of a cosmetic containing the human IFN-inducing substance of the present invention will be described. The amount of the human IFN-inducing substance of the present invention to be added to the present invention is not particularly limited, but is usually
0.001 to 20.00% by weight (hereinafter abbreviated as wt%) is used. Considering the effects of odor and coloring on the product and the effects on the skin, 0.1 to 5.0 wt% is desirable. The formulation does not impose any restrictions on the skin composition of the present invention. Formulation Example 1 Cream (wt%) Aqueous phase: dipropylene glycol 2.0 glycerin 3.0 Purified water 30.0 Osteoclastic supplement extract of Experimental Example 1 Oil phase: cetanol 8.0 Jojoba oil 5.0 Squalane 37.5 Beeswax 6.0 Emulsifier: lipophilic glyceryl monostearate 2.0 Polyoxyethylene sorbitan monolaurate (20.EO) 2.0 Perfume Appropriate Preservative Appropriate [Preparation method] Mix and heat to 70 ° C
And maintain the aqueous phase. On the other hand, other components are mixed, dissolved by heating, and kept at 70 ° C. to obtain an oil phase. The oil phase is added to the aqueous phase to emulsify, and cooled to 30 ° C. to obtain a cream of the product. Formulation Example 2 Creamy foundation (wt%) Pigment: Titanium oxide 8.0 Kaolin 5.0 Talc 2.0 Bentonite 1.0 Color pigment Appropriate amount Water phase: Triethanolamine 1.2 Sorbit 3.0 Purified water 50.0 Banana extract of Experimental Example 2 1.0 Oil phase: Stearic acid 5.0 Glycerin monostearate 2.5 Cetanol 1.0 Propylene glycol monolaurate 3.0 Squalane 7.0 Cetyl octanoate 8.0 Fragrance Appropriate amount Preservative Appropriate amount Preparation Method An aqueous phase is prepared, mixed with a pigment, dispersed, and then heated to 75 ° C. Prepare the oil phase and heat to 80 ° C. The oil phase is added to the aqueous phase while stirring to emulsify, then cooled, flavor is added, and cooled to 30 ° C. to obtain the product. Formulation Example 3 Lipstick (wt%) Base: Spicy extract 1.0 Castor oil 45.0 Hexadecyl alcohol 25.0 Beeswax 5.0 Candelilla wax 7.0 Carnauba wax 6.0 Lanolin 4.0 Coloring material: Titanium oxide 2.0 Coloring agent Appropriate amount Fragrance Appropriate amount Manufacturing method The base material is heated and melted, and the coloring material is added and kneaded with a roll mill to uniformly disperse the coloring material. Then re-melt, add fragrance and pour into mold to get product lipstick. Effects of the Invention In order to clarify the effects of the present invention, use tests by humans were performed. Test Example 4 The cream shown in Formulation Example 1 and the cream from which the IFN-inducing substance according to the present invention was removed were applied to 10 panelists for 1 month on the left, right and right faces of the face for one month. Continuous application, then skin glue, shine,
Sensory evaluation was performed on four items of freshness and smoothness. Table 4 shows the evaluation criteria for the sensory evaluation performed in Test Example 4. Each of the skin shine, gloss, freshness, and smoothness was represented by a five-point scale from 1 point of "almost no" to 5 points of "very much". [Table 4] Table 5 shows the results of Test Example 4. The numbers in the table are the average scores of 10 panelists evaluated based on the evaluation criteria in Table 4. As is clear from the results in Table 5,
The cosmetic containing the human IFN-inducing substance of the present invention exhibited an excellent skin conditioning effect as compared with the control product. [Table 5]

──────────────────────────────────────────────────続 き Continuation of the front page (56) References JP-A-60-258104 (JP, A) JP-A-6-256205 (JP, A) JP-A-6-183986 (JP, A) JP-A-7- 277944 (JP, A) JP-A-7-61920 (JP, A) JP-A-7-187949 (JP, A) JP-A-57-185210 (JP, A) JP-A-2-111710 (JP, A) JP-A-64-61415 (JP, A) JP-A-3-190809 (JP, A) JP-A-63-5710 (JP, A) JP-A-62-142120 (JP, A) JP-A-6-1222619 JP-A-63-303908 (JP, A) JP-A-60-109509 (JP, A) JP-A-62-234006 (JP, A) JP-A-4-82816 (JP, A) JP-A-5-246874 (JP, A) JP-A-4-82814 (JP, A) JP-A-6-24937 (JP, A) JP-A-5-286824 ( P, A) (58) investigated the field (Int.Cl. ^7, DB name) A61K 7/00 - 7/50 A61K 35/78

Claims (1)

(57) [Claim 1] As a human interferon inducer,
A cosmetic comprising 0.1 to 5.0% by weight of a substance extracted from pea thorn beans, Mongo Kureiso, self-defense and banana.